振东制药(300158.SZ)：阴道用乳杆菌二联活菌胶囊的新药申请获受理

Core Viewpoint - The new drug application (NDA) for the core product "Vaginal Lactobacillus Dual Live Bacteria Capsules" of Guangdong Longchuang Biopharmaceutical Co., Ltd. has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China [1] Group 1 - The product is a compound preparation primarily composed of Lactobacillus gasseri and Lactobacillus rhamnosus live bacteria [1] - The drug is intended for the restoration of vaginal flora and the treatment of bacterial vaginosis [1]